Predictive and diagnostic value of MCP-1, MIF, and ICAM-1 in Type-2 diabetes mellitus patients with diabetic kidney disease

MCP-1、MIF 和 ICAM-1 在 2 型糖尿病合并糖尿病肾病患者中的预测和诊断价值

阅读:2

Abstract

OBJECTIVE: To explore the predictive value of monocyte chemoattractant protein-1 (MCP-1), macrophage migration inhibitory factor (MIF), and intercellular adhesion molecule-1 (ICAM-1) in patients with Type-2 diabetes mellitus (T2DM) complicated by diabetic kidney disease (DKD). METHODS: This cross-sectional retrospective study included T2DN patients admitted to the Nephrology Department of Lanzhou University Second Hospital from September, 2022 to March, 2024. DKD was assessed by measuring the ratio of urinary albumin to creatinine. A Receiver Operating Characteristic (ROC) analysis was performed to evaluate the predictive value of MCP-1, MIF, and ICAM-1 for DKD. RESULTS: A total of 241 patients were included, predominantly 158 males (65.6%), with a median age of 60 (53-69) years. Sixty-seven patients had no DKD (normal proteinuria), while 174 patients presented with DKD; of them, 95 cases had microalbuminuria, and 79 cases had high proteinuria. The MCP-1, MIF, and ICAM-1 levels in the high-proteinuria group were significantly higher than in other groups (all P<0.05). The multivariate logistic regression analysis showed that high levels of MCP-1, MIF, and ICAM-1 are risk factors for the development of DKD. ROC analysis demonstrated that the area under the curve (AUC) of MCP-1, MIF, and ICAM-1 for diagnosing DKD were 0.895 (95% CI: 0.857-0.933, P<0.001), 0.719 (95% CI: 0.653-0.785, P<0.001), and 0.827 (95% CI: 0.773-0.880, P<0.001), respectively. The combined prediction of DKD by the three factors was 0.941 (95% CI: 0.914-0.968, P<0.001). CONCLUSIONS: MCP-1, MIF, and ICAM-1 are risk factors for developing DKD. A combination of these indexes may have a good predictive value for DKD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。